A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors

Trial ID or NCT#



not recruiting iconNOT RECRUITING


The purpose of this study is to evaluate the safety and tolerability of HGS1029 in subjects with advanced solid tumors and to determine a phase 2 dose.

Official Title

A Phase 1 Dose-Escalation Study to Evaluate the Safety and Tolerability of HGS1029 (AEG40826-2HCl) in Patients With Advanced Solid Tumors

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Confirmed advanced solid malignancy - Life expectancy of at least 3 months - Age 18 years or older - Acceptable liver function - Acceptable renal function - Acceptable hematologic status
Exclusion Criteria:
  1. - Received investigational (not yet approved by a regulatory authority)agent within 4 weeks before enrollment. - Received non-investigational agent within 3 weeks before enrollment. - Progressive CNS involvement including the need of corticosteroids - Pregnant or breast-feeding women - Active, uncontrolled bacterial, viral, or fungal infections within 2 weeks of Cycle 1 Day 1 - Known HIV infection


Heather Wakelee
Heather Wakelee
Medical oncologist, Thoracic specialist
Winston Chen and Phyllis Huang Professor
A. Dimitrios Colevas, MD
A. Dimitrios Colevas, MD
Medical oncologist, Head and neck specialist, Cutaneous oncology specialist
Professor of Medicine (Oncology) and, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS) and of Radiation Oncology (Radiation Therapy)
George A. Fisher Jr.
George A. Fisher Jr.
Medical oncologist, Gastrointestinal specialist
Colleen Haas Chair in the School of Medicine

Contact us to find out if this trial is right for you.


Cancer Clinical Trials Office